- Home
- AMLX vs CRVS Comparison
AMLX vs CRVS Comparison
Compare AMLX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMLX | CRVS |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 634.0M |
| IPO Year | 2022 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AMLX | CRVS |
|---|---|---|
| Price | $13.25 | $8.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $17.43 | $13.75 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.60 | $2.54 |
| 52 Week High | $16.96 | $9.60 |
Technical Indicators
Market Signals| Indicator | AMLX | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 51.32 |
| Support Level | $12.69 | $8.31 |
| Resistance Level | $15.06 | $9.60 |
| Average True Range (ATR) | 0.76 | 0.54 |
| MACD | -0.16 | -0.09 |
| Stochastic Oscillator | 21.48 | 26.75 |
Price Performance
Historical ComparisonAbout AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).